Stocktoria
CABOT CORP CBT
CABOT CORP (CBT) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.99% (safety: safe). FY2025 revenue was $3.7B at a 8.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-25 | Mizuho | Neutral (main) |
| 2026-06-08 | Truist Securities | Buy (init) |
| 2026-05-13 | JP Morgan | Underweight (main) |
| 2026-05-08 | UBS | Neutral (main) |
| 2026-05-06 | Mizuho | Neutral (main) |
| 2026-02-05 | UBS | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.153 |
| Retained earnings / assets | 0.481 |
| EBIT / assets | 0.163 |
| Equity / liabilities | 0.808 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CBT | CABOT CORP | 6/9 | 4.51 | 14.6 | -7% |
| OEC | Orion S.A. | 3/9 | 1.08 | — | -3.8% |
| WDFC | WD 40 CO | 7/9 | 9.05 | 33.7 | +5% |
| FTK | FLOTEK INDUSTRIES INC/CN/ | 4/9 | -0.95 | 26.3 | +26.9% |
| ARQ | Arq, Inc. | 2/9 | 1.53 | — | +10.4% |
| FSI | FLEXIBLE SOLUTIONS INTERNATIONAL INC | 5/9 | 6.24 | 110.2 | +0.7% |
| ASPI | ASP Isotopes Inc. | 5/9 | 3.69 | — | — |
About CABOT CORP
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals. The company offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions. It also provides specialty carbons for use in inks, coatings, plastics, adhesives, toners, batteries, and displays; conductive additives and fumed alumina used in lead acid and lithium-ion batteries for electric vehicles; fumed silica used in adhesives, sealants, cosmetics, batteries, inks, toners, silicone elastomers, coatings, polishing slurries, and pharmaceuticals; and fumed alumina for use in various products, including inkjet media, lighting, coatings, cosmetics, and polishing slurries. In addition, it offers aerogel, a hydrophobic, silica-based particle to use in various thermal insulation and specialty chemical applications; masterbatch and conductive compound products that are used in automotive, industrial, packaging, infrastructure, agriculture, consumer products, and electronics industries; and inkjet colorants for inkjet printing applications, as well as carbon nanotubes and fumed metal oxides. The company sells its products through distributors and sales representatives in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Cabot Corporation was founded in 1882 and is headquartered in Boston, Massachusetts.
FAQ
Is CBT financially healthy?
CABOT CORP's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CBT pay a dividend, and is it safe?
Yes. CABOT CORP pays a dividend yielding about 1.99% with a 29.0% payout ratio, rated “safe” for safety.
How profitable is CBT?
In FY2025, CABOT CORP had a net margin of 8.9% and a return on equity of 19.4%.
Is CBT overvalued or undervalued?
CABOT CORP trades at about 14.3× trailing earnings — below its 10-year norm (10-year range 8.6×–22.5×, median 16.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CBT?
The average Wall-Street price target for CABOT CORP is $88.50, about 2.5% above the recent price, from 6 analysts (consensus: buy).
Is CBT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CABOT CORP: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 14.6×, a dividend yield of 1.99%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.